Ultomiris (ravulizumab-cwvz) Indication(s): Multiple rare, complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD) Manufacturer(s): Alexion/AstraZeneca 2024 Sales: $3.92 billion Why it sold so well: Ultomiris, developed by Alexion, AstraZeneca Rare Disease, is emerging as a hematology drug to watch in 2025, driven by strong commercial momentum and expanding clinical uptake in 2024
Not only will these healthy GLP-1 meals help you feel satisfied and energized, but youll find that theyre easy to makeand did we mention that theyre delicious, too
Isoprenaline control rats demonstrated marked dilatation and congestion of blood vessels in the portal tracts of the liver, as well as dilatation of central veins and sinusoids in the liver parenchyma
1 But they have also proven to be effective in helping people lose weight, and three GLP-1 drugs Wegovy, Zepbound, and Saxenda have FDA approval to be used for chronic weight management
1 yrCN4.0/5.0 22% Reorder rate 415 Interested customers 3/3 Matches all Premium Private Label Ghk -cu Blue Copper Peptide Ampoule Serum GHK CU Anti Aging Firming Repair Hydrating Facial Skin $7-8 Min
